$PSNL

Tachibana Aaron sold $480K of PSNL

Tachibana Aaron (CFO AND COO) sold 40,000 shares of Personalis, Inc. (PSNL) at $12.01 ($0.48M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tachibana Aaron
Published Jun 6, 2026, 12:19 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 6, 2026, 12:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PSNL
Neutral
medium confidence
Mentioned
$PSNL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PSNLNeutralLow
01

Why it matters

The disclosure provides a measurable insider behavior datapoint (40,000 shares at $12.0100) but does not, by itself, establish a new fundamental driver.

02

Market read

For PSNL, this is a sentiment/positioning input rather than a catalyst; any trading impact is likely small and short-lived.

03

What to watch

Traders may over-weight the sale without checking whether other insiders/funds simultaneously bought or whether the company has upcoming catalysts (earnings, trial updates) not mentioned here.

Relevance 6/10Novelty 6/10Timing: Filed June 5; sale executed June 4 (after-hours/next-session read-through).

Background

SEC Form 4 reports an officer’s transaction in the issuer’s own shares; 10b5-1 indicates the trade was pre-scheduled under SEC rules.

Company-level read

Ticker impact

$PSNLNeutralMedium confidence
Context

Personalis CFO/COO Tachibana Aaron sold 40,000 PSNL shares for ~$480.4K under a pre-arranged 10b5-1 plan, per SEC Form 4.

Expected impact

Low-to-moderate short-term downside bias possible, but impact likely muted versus non-10b5-1 sales.

Evidence & confidence

The filing is a concrete datapoint (sale size, price, date) but explicitly tied to a pre-arranged 10b5-1 plan, reducing interpretive weight.

Market effects

Limited sector read-through; this is company-specific insider activity with no stated operational/regulatory catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect routine liquidity needs rather than negative fundamentals; price reaction could be overstated.

Key entities

  • Personalis, Inc.

    US-listed company (PSNL) whose officer sold shares disclosed in SEC Form 4.

  • Tachibana Aaron

    CFO and COO who executed an open-market sale under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MRNAHighAI 9/10

Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation — BigGo Finance

Moderna and Merck's personalized mRNA cancer vaccine (mRNA-4157) met its primary endpoint in Phase 3 trials, boosting their market value by over $50 billion. The success highlights the role of sequencing companies like Tempus AI and Personalis, which provide genetic profiling for personalized vaccines. Tempus AI's planned acquisition of Personalis faces competition as Personalis' stock surpasses the offer price, sparking speculation of a bidding war. The deal's strategic value lies in Personalis

$PSNLMed

Personalis (PSNL) Has Investors Asking A Fresh Question

Personalis (PSNL) received a new $18.3M task order from the U.S. Department of Veterans Affairs, bringing its cumulative VA MVP task orders to $243.3M. The stock has seen significant gains, with a 30-day return of 42.57% and a year-to-date gain of 117.58%. Analysts estimate a fair value of $15.44 per share, suggesting the stock is overvalued at its last close of $17.08. Investors should consider risks such as delayed reimbursements and potential underperformance of large contracts.

$PSNLHighAI 8/10

Personalis Stock Jumps As Tempus AI Acquisition Reshapes Outlook

Personalis Inc. (PSNL) stock rose 9.41% after reporting Q2 revenue of $22.4M, exceeding consensus estimates. The company agreed to be acquired by Tempus AI for $16.25 per share. Clinical volume for its NeXT Personal MRD test surged 199% year over year, with guidance for over 500% clinical revenue growth in 2026. Management will halt guidance and earnings calls as the company pivots to a merger-driven setup.

$TEMHighAI 9/10

Moderna’s Cancer Breakthrough Just Made Tempus AI’s $1.5 Billion Bet Look Brilliant

Tempus AI agreed to acquire Personalis for $1.5B in July 2026. Personalis' tech supports Moderna and Merck's mRNA cancer vaccine, which showed positive Phase 3 results in August 2026. Tempus shares rose 23.91% on the news. Personalis' revenue grew 441.6% YoY in Q2 2026. Tempus reported $382.5M in Q2 2026 revenue, up 22% YoY. The deal is expected to close late Q4 2026 or early 2027.